NCT00535418View on ClinicalTrials.gov

Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

June 30, 2000

Primary Completion Date

July 31, 2002

Conditions
Breast Cancer
Interventions
DRUG

Letrozole

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT00535418 - Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers | Biotech Hunter | Biotech Hunter